Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function
about
Animal and in silico models for the study of sarcomeric cardiomyopathiesMutation-Specific Phenotypes in hiPSC-Derived Cardiomyocytes Carrying Either Myosin-Binding Protein C Or α-Tropomyosin Mutation for Hypertrophic Cardiomyopathy.The embryological basis of subclinical hypertrophic cardiomyopathyResearch priorities in sarcomeric cardiomyopathiesLong term ablation of protein kinase A (PKA)-mediated cardiac troponin I phosphorylation leads to excitation-contraction uncoupling and diastolic dysfunction in a knock-in mouse model of hypertrophic cardiomyopathyMybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in miceIncreased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in micePerturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutationsRescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in miceMYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correctionSmall and large animal models in cardiac contraction research: advantages and disadvantagesEpigallocatechin-3-Gallate Accelerates Relaxation and Ca2+ Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice.FRET biosensor uncovers cAMP nano-domains at β-adrenergic targets that dictate precise tuning of cardiac contractility.Genotype-specific pathogenic effects in human dilated cardiomyopathy.Differences in the regulation of RyR2 from human, sheep, and rat by Ca²⁺ and Mg²⁺ in the cytoplasm and in the lumen of the sarcoplasmic reticulum.Surviving the infarct: A profile of cardiac myosin binding protein-C pathogenicity, diagnostic utility, and proteomics in the ischemic myocardium.Troponin I phosphorylation in human myocardium in health and disease.Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue.FHL2 expression and variants in hypertrophic cardiomyopathy.Length-dependent changes in contractile dynamics are blunted due to cardiac myosin binding protein-C ablation.Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathyPhosphorylation of cardiac Myosin-binding protein-C is a critical mediator of diastolic functionImpact of site-specific phosphorylation of protein kinase A sites Ser23 and Ser24 of cardiac troponin I in human cardiomyocytesCardiac Myosin Binding Protein-C Phosphorylation Modulates Myofilament Length-Dependent ActivationS-glutathiolation impairs phosphoregulation and function of cardiac myosin-binding protein C in human heart failure.Impaired contractile function due to decreased cardiac myosin binding protein C content in the sarcomereContractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.Cardiac myosin-binding protein C: hypertrophic cardiomyopathy mutations and structure-function relationships.Cardiac myosin-binding protein-C is a critical mediator of diastolic function.Contribution of Post-translational Phosphorylation to Sarcomere-Linked Cardiomyopathy Phenotypes.Proteasome dysfunction in cardiomyopathies.The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy-Progress and Novel Therapeutic Opportunities.Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model.Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study).Pathogenesis associated with a restrictive cardiomyopathy mutant in cardiac troponin T is due to reduced protein stability and greatly increased myofilament Ca2+ sensitivity.Familial hypertrophic cardiomyopathy: functional variance among individual cardiomyocytes as a trigger of FHC-phenotype development.Mechanical aberrations in hypetrophic cardiomyopathy: emerging concepts.Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy.
P2860
Q26865437-06C77CB3-B5D6-43B4-90F9-17C0E8A73560Q27314792-6C40392E-1FB9-40D4-9A2D-2EF488A828BCQ27342687-B0CFFC20-73E7-481C-8C1A-4526FB06F74DQ27694507-DBE1B9EB-58BE-4C93-88E0-CD933999222DQ28242903-FBDA668A-D1E1-4D81-8CB5-F02D3114005EQ28253008-D749902A-DD4F-44D8-A9F1-C96146EA1BA1Q28263306-4FE4EC40-37F9-47D7-A6F3-6339039FC2D4Q28287468-E363BEBF-82C2-4E7E-8BED-67759301B43EQ28291547-F1A7DC8A-AF3C-4082-A7B0-073AC74A8620Q28304022-88C617CB-F3E0-4F9D-BAB5-14CA02FF7A99Q28658055-DFD28B0E-04C2-42B3-AB73-AFC5E82009C6Q30830714-F0D049DA-C84A-4FA6-9134-06F1CD1A8221Q33622017-16172209-2D2E-497A-B96F-51F59B3ECE3AQ33903336-4F1347C2-DFF8-4C4E-91DE-2EBD394756ACQ34088867-12B90B18-B1CF-43CB-87CA-5B9A3AC9E3F7Q34172185-4CD16E23-AA2C-4C0C-BE16-CE3DC16C97DDQ34302767-9C377AF5-46A3-4ABE-8F6A-D84CA075934CQ34338236-F2B4FBB3-2A64-42D7-B8BB-67B6D2F0B9B4Q34430364-4FB91158-43B8-41F1-B7B9-5643FA0F3AD1Q34608313-ADA84973-0022-4BE6-8678-CA8CFA0C4162Q34626001-703C9CFE-4FBA-4AF8-97EB-A416C77B9F78Q35659681-195E2C04-30E5-4B95-939E-E697F2C751F5Q36528069-06B9F3CA-CE53-401A-946D-4EFA3157281BQ36579173-AFAFA466-A9B5-49E0-B3D3-DCF0E83AEDA7Q36812041-6A779274-5E7C-4793-94E5-C5412795BDFEQ37054964-77609674-515C-4BD0-8BA4-665F8B05066AQ37629210-3D749384-7C53-4302-A27B-C97BEFAC08B2Q38163334-5660EB6B-4E11-4DD9-80F4-CB5914785CD8Q38179957-56904218-CBB9-4F01-B600-27A8FE0DB4ECQ38816583-8BA8778E-58B0-47F1-9675-EA86BC89784FQ38970493-DABFC8A8-ABD7-461A-ABA9-78CA8F8A1251Q38978665-FAAFF674-BFED-4418-A0FB-33A0347E06AFQ40042653-A8C65C67-1AF0-4857-BE84-327D5B052B71Q41203153-A27D8F40-5336-4877-B7AB-1170A831FCDDQ41700317-5F54EEB5-2D77-4B45-95B3-29B11A04E29CQ41815143-D0B895B2-42CB-4381-8DE6-97A45FE5E3E8Q41949346-387C5862-3908-4C1E-B108-1BF70A790EB5Q41982072-5B5D0263-7D58-46F3-87B5-E9BAD6FE28F7Q42622003-3A7ED379-6B63-4D4C-B1CE-77B75CD45D72Q44354566-503331D9-704C-4639-B72A-DEA52E79424D
P2860
Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Contractile dysfunction irresp ...... with normal systolic function
@ast
Contractile dysfunction irresp ...... with normal systolic function
@en
Contractile dysfunction irresp ...... with normal systolic function
@nl
type
label
Contractile dysfunction irresp ...... with normal systolic function
@ast
Contractile dysfunction irresp ...... with normal systolic function
@en
Contractile dysfunction irresp ...... with normal systolic function
@nl
prefLabel
Contractile dysfunction irresp ...... with normal systolic function
@ast
Contractile dysfunction irresp ...... with normal systolic function
@en
Contractile dysfunction irresp ...... with normal systolic function
@nl
P2093
P3181
P1476
Contractile dysfunction irresp ...... with normal systolic function
@en
P2093
Aref Najafi
Cris dos Remedios
Dennis Dooijes
Diederik W D Kuster
E Rosalie Paalberends
Folkert J ten Cate
Ger J M Stienen
Marjon van Slegtenhorst
Michelle Michels
Nicky M Boontje
P3181
P356
10.1161/CIRCHEARTFAILURE.111.963702
P407
P577
2012-01-01T00:00:00Z